市场调查报告书
商品编码
1603779
到 2030 年牙科移植骨替代物市场预测:按产品、材料、形式、应用、最终用户和地区进行的全球分析Dental Bone Graft Substitutes Market Forecasts to 2030 - Global Analysis By Product, Material, Form, Application, End User and By Geography |
根据Stratistics MRC预测,2024年全球牙科移植骨替代物市场规模将达到13.5亿美元,并在预测期内以9.7%的复合年增长率成长,到2030年将达到21.7亿美元。
牙科移植骨替代物是用于促进骨质缺乏、受损或吸收区域的骨再生和癒合的生物材料。这些替代品可作为新骨生长的支架,有助于人工植牙、牙周病修復和下颚骨重组。这些替代品提供了一致性、易用性和结构支撑,使其在现代牙科和颚颜面手术中恢復骨量和密度方面发挥着重要作用。
根据《国际牙科论坛报》2021 年 6 月发表的报导,许多患者正在要求植入治疗,这是骨移植生长的一个有希望的指标。
口腔健康意识不断增强
随着人们越来越了解维持牙齿和牙龈健康的重要性,预防性治疗也越来越受到关注,包括植入、牙周手术和骨头移植术。这种认知导致对牙科移植骨替代物,这对于恢復骨量和支撑植入至关重要。此外,对先进治疗方案的了解不断增加,导致患者选择更有效、更长期的解决方案,推动市场成长。
併发症的风险
牙科移植骨替代物的併发症风险,例如感染疾病、移植物排斥和骨整合不足,可能会阻止患者选择该手术。这些併发症可能导致癒合延迟、需要额外手术或治疗结果不佳。因此,患者可能不愿意接受移植手术,这可能会对替代品的需求产生负面影响。对副作用和术后挑战的恐惧阻碍了市场的成长,尤其是在高风险族群中。
改善医疗基础设施
设备齐全的牙科诊所、专业的设施和训练有素的专业人员可以让患者得到更有效、更及时的治疗。这有助于引入先进的牙科治疗方法,包括植入和骨移植。此外,加强基础设施将促进创新植入材料的研究和开发并改善治疗效果。随着医疗保健系统的现代化,人们对口腔健康的认识不断提高,导致对移植骨替代物的需求增加,进一步推动市场扩张。
治疗费用高
牙科移植骨替代物的高治疗成本是由于所使用的先进材料(合成骨、同种异体移植物、异质骨移植等)、复杂的程序以及对熟练专业人员的需求造成的。这些费用包括移植材料、手术过程和术后护理的价格。这些经济负担限制了可近性,特别是对于发展中地区和未投保的患者。因此,许多患者推迟或避免治疗,阻碍了市场成长。
COVID-19 的影响
COVID-19 大流行扰乱了供应链、推迟了选择性牙科手术并限制了患者获得牙科护理的机会,从而对牙科移植骨替代物市场产生了重大影响。封锁和健康问题在短期内减少了对牙科治疗(包括骨移植)的需求。然而,随着情况的改善和牙科诊所恢復正常业务,由于口腔卫生意识的提高和择期手术的恢復,对骨移植的需求回升。
预计同种异体骨替代品市场在预测期内将是最大的
预计同种异体移植骨替代物细分市场将在整个预测期内获得最大的市场占有率。同种异体骨替代物是从人体尸体骨中提取的材料,通常经过处理以去除活细胞以降低免疫排斥的风险。它在各种整形外科手术和牙科治疗(例如人工植牙和下颚骨重组)中用作新骨的支架。使用同种异体移植物可以减少额外手术的需要和供体部位的发生率。
预计人工植牙细分市场在预测期内复合年增长率最高。
预计人工植牙细分市场在预测期内复合年增长率最高。在人工植牙领域,移植骨替代物已被证明可以透过为骨不足或受损区域的植入植入提供结构支撑来提高人工植牙的成功率。在植入治疗中使用移植骨替代物对于改善因创伤、牙周病或先天性缺陷而导致骨质流失的患者的治疗效果以及提高整体植入成功率至关重要。
由于人们对牙科保健意识的提高、可支配收入的增加和人口老化的加剧,预计亚太地区将在预测期内创下最大的市场占有率。印度、中国和日本等国家由于患者人数众多且获得先进牙科护理的机会有所改善,因此成为主要贡献者。此外,政府的倡议和创新生医材料的采用预计将在未来几年推动该地区的市场扩张。
由于对植入的需求不断增加以及牙科疾病的高发生率,预计北美在预测期内的复合年增长率最高。该地区受益于先进的医疗基础设施、广泛的口腔健康意识和高可支配收入。尤其是美国,其对合成骨和同种异体骨等创新骨移植材料的强劲需求引领市场。此外,微创牙科手术的采用和生物材料的技术进步预计将推动北美市场的成长。
According to Stratistics MRC, the Global Dental Bone Graft Substitutes Market is accounted for $1.35 billion in 2024 and is expected to reach $2.17 billion by 2030 growing at a CAGR of 9.7% during the forecast period. Dental bone graft substitutes are biomaterials used to promote bone regeneration and healing in areas where bone is insufficient, damaged, or resorbed. These substitutes serve as a scaffold for new bone growth, aiding in dental implant placement, periodontal repairs, and jaw reconstruction. They offers compatibility, ease of use, and structural support, making them essential in modern dental and maxillofacial procedures for restoring bone volume and density.
According to the article published by Dental Tribune International in June 2021, a large volume of patients demanded an implant procedure, which is a promising indicator for the growth of bone grafting.
Rising awareness of oral health
As people become more informed about the importance of maintaining healthy teeth and gums, there is an increased focus on preventive care, including dental implants, periodontal surgeries, and bone grafting procedures. This awareness leads to higher demand for dental bone graft substitutes, as they are essential for restoring bone volume and supporting implants. Additionally, greater knowledge of advanced treatment options drives patients to choose more effective, long-term solutions, thereby fueling market growth.
Risk of complications
The risk of complications in dental bone graft substitutes, such as infections, graft rejection, or insufficient bone integration, can deter patients from opting for the procedure. These complications may lead to delayed healing, the need for additional surgeries, or poor treatment outcomes. As a result, patients may hesitate to undergo grafting procedures, negatively impacting demand for substitutes. The fear of adverse effects and post-surgical challenges, especially among risk-prone individuals, hampers the market growth.
Improved healthcare infrastructure
With better-equipped dental clinics, specialized facilities, and trained professionals, patients can receive more effective and timely treatments. This fosters the adoption of advanced dental procedures, including dental implants and bone grafting. Additionally, enhanced infrastructure promotes research and development of innovative grafting materials, improving treatment outcomes. As healthcare systems modernize, there is greater awareness of oral health, leading to increased demand for bone graft substitutes, further driving market expansion.
High treatment costs
High treatment costs in dental bone graft substitutes arise due to the advanced materials used (such as synthetic, allografts, and xenografts), complex procedures, and the need for skilled professionals. These costs can include the price of the graft material, surgical procedures, and post-operative care. This financial burden limits accessibility, particularly in developing regions or for uninsured patients. As a result, many individuals may delay or avoid treatment, hindering market growth.
Covid-19 Impact
The covid-19 pandemic significantly impacted the dental bone graft substitutes market by disrupting supply chains, delaying elective dental procedures, and limiting patient access to dental care. With lockdowns and health concerns, demand for dental treatments, including bone grafts, declined in the short term. However, as the situation improved and dental practices resumed normal operations, there was a resurgence in demand for bone graft substitutes, driven by increased awareness of oral health and the recovery of elective surgeries.
The allograft bone graft substitutes segment is expected to be the largest during the forecast period
The allograft bone graft substitutes segment is predicted to secure the largest market share throughout the forecast period. Allograft bone graft substitutes are materials derived from human cadaveric bone, typically processed to remove any living cells to reduce the risk of immune rejection. They serve as a scaffold for new bone growth in various orthopedic and dental procedures, such as dental implants and jaw reconstruction. The use of allografts reduces the need for additional surgery and donor site morbidity.
The dental implantology segment is expected to have the highest CAGR during the forecast period
The dental implantology segment is anticipated to witness the highest CAGR during the forecast period. In dental implantology, dental bone graft substitutes play a crucial role in enhancing the success of dental implants by providing structural support for implant placement in areas with insufficient or damaged bone. The use of bone graft substitutes in implantology is essential for improving outcomes in patients with bone loss due to trauma, periodontal disease, or congenital defects, enhancing overall implant success rates.
Asia Pacific is expected to register the largest market share during the forecast period driven by increasing dental healthcare awareness, rising disposable incomes, and a growing aging population. Countries like India, China, and Japan are key contributors due to their large patient base and improving access to advanced dental treatments. Additionally, government initiatives and the adoption of innovative biomaterials are expected to fuel market expansion in the region over the coming years.
North America is projected to witness the highest CAGR over the forecast period due to a high prevalence of dental issues, alongside an increasing demand for dental implants. The region benefits from advanced healthcare infrastructure, widespread awareness of oral health, and high disposable incomes. The United States, in particular, leads the market with significant demand for innovative bone graft materials like synthetic and allografts. Additionally, the adoption of minimally invasive dental procedures and technological advancements in biomaterials are expected to drive market growth in North America.
Key players in the market
Some of the key players profiled in the Dental Bone Graft Substitutes Market include Medtronic, Geistlich Pharma, Zimmer Biomet, Dentsply Sirona, Straumann Group, BioHorizons, Nobel Biocare, Ace Surgical Supply, RTI Surgical, Dentium, Botiss Biomaterials, Septodont, Osteogenics Biomedical, Biomatlante, Collagen Matrix, Implant Direct Sybron International, Institut Straumann, Maxigen Biotech, Sunstar Americas and Lifenet Health.
In October 2024, Geistlich Pharma launched the Bio-Oss(R) Pen, an applicator designed to improve the precision of its Bio-Oss(R) bone graft material application. This innovation aims to enhance user control, making it easier to apply the bone graft in minimally invasive surgeries and challenging clinical scenarios.
In October 2024, Nobel Biocare, in partnership with Mimetis Biomaterials, introduced creos(TM) syntogain, a biomimetic synthetic bone graft. Made of 80% calcium-deficient hydroxyapatite (CDHA) and 20% B-tricalcium phosphate, it closely mimics natural bone for enhanced osteoconduction and stability, intended to support efficient regeneration in dental procedures.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.